254 related articles for article (PubMed ID: 34566847)
1. Therapeutic Potential of Sodium Channel Blockers as a Targeted Therapy Approach in
Lauxmann S; Sonnenberg L; Koch NA; Bosselmann C; Winter N; Schwarz N; Wuttke TV; Hedrich UBS; Liu Y; Lerche H; Benda J; Kegele J
Front Neurol; 2021; 12():703970. PubMed ID: 34566847
[No Abstract] [Full Text] [Related]
2. An activator of voltage-gated K
Servettini I; Talani G; Megaro A; Setzu MD; Biggio F; Briffa M; Guglielmi L; Savalli N; Binda F; Delicata F; Bru-Mercier G; Vassallo N; Maglione V; Cauchi RJ; Di Pardo A; Collu M; Imbrici P; Catacuzzeno L; D'Adamo MC; Olcese R; Pessia M
Proc Natl Acad Sci U S A; 2023 Aug; 120(31):e2207978120. PubMed ID: 37487086
[TBL] [Abstract][Full Text] [Related]
3. Episodic ataxia type 1 mutations in the KCNA1 gene impair the fast inactivation properties of the human potassium channels Kv1.4-1.1/Kvbeta1.1 and Kv1.4-1.1/Kvbeta1.2.
Imbrici P; D'Adamo MC; Kullmann DM; Pessia M
Eur J Neurosci; 2006 Dec; 24(11):3073-83. PubMed ID: 17156368
[TBL] [Abstract][Full Text] [Related]
4. Kv1.1 Channelopathies: Pathophysiological Mechanisms and Therapeutic Approaches.
D'Adamo MC; Liantonio A; Rolland JF; Pessia M; Imbrici P
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331416
[TBL] [Abstract][Full Text] [Related]
5. A novel KCNA1 mutation in a patient with paroxysmal ataxia, myokymia, painful contractures and metabolic dysfunctions.
Imbrici P; Altamura C; Gualandi F; Mangiatordi GF; Neri M; De Maria G; Ferlini A; Padovani A; D'Adamo MC; Nicolotti O; Pessia M; Conte D; Filosto M; Desaphy JF
Mol Cell Neurosci; 2017 Sep; 83():6-12. PubMed ID: 28666963
[TBL] [Abstract][Full Text] [Related]
6. Kcna1-mutant rats dominantly display myokymia, neuromyotonia and spontaneous epileptic seizures.
Ishida S; Sakamoto Y; Nishio T; Baulac S; Kuwamura M; Ohno Y; Takizawa A; Kaneko S; Serikawa T; Mashimo T
Brain Res; 2012 Jan; 1435():154-66. PubMed ID: 22206926
[TBL] [Abstract][Full Text] [Related]
7. Two novel KCNA1 variants identified in two unrelated Chinese families affected by episodic ataxia type 1 and neurodevelopmental disorders.
Yuan H; Yuan H; Wang Q; Ye W; Yao R; Xu W; Liu Y
Mol Genet Genomic Med; 2020 Oct; 8(10):e1434. PubMed ID: 32705822
[TBL] [Abstract][Full Text] [Related]
8. Case report: A novel loss-of-function pathogenic variant in the KCNA1 cytoplasmic N-terminus causing carbamazepine-responsive type 1 episodic ataxia.
Manville RW; Sidlow R; Abbott GW
Front Neurol; 2022; 13():975849. PubMed ID: 36016548
[TBL] [Abstract][Full Text] [Related]
9. [Hereditary episodic ataxia].
Riant F; Vahedi K; Tournier-Lasserve E
Rev Neurol (Paris); 2011 May; 167(5):401-7. PubMed ID: 21492892
[TBL] [Abstract][Full Text] [Related]
10. Isoform-Selective KCNA1 Potassium Channel Openers Built from Glycine.
Manville RW; Abbott GW
J Pharmacol Exp Ther; 2020 Jun; 373(3):391-401. PubMed ID: 32217768
[TBL] [Abstract][Full Text] [Related]
11. Episodic ataxias 1 and 2.
Baloh RW
Handb Clin Neurol; 2012; 103():595-602. PubMed ID: 21827920
[TBL] [Abstract][Full Text] [Related]
12. Identification of a New
Karalok ZS; Megaro A; Cenciarini M; Guven A; Hasan SM; Taskin BD; Imbrici P; Ceylaner S; Pessia M; D'Adamo MC
Front Neurol; 2018; 9():587. PubMed ID: 30140249
[TBL] [Abstract][Full Text] [Related]
13. Novel Genetic Variants Expand the Functional, Molecular, and Pathological Diversity of
Paulhus K; Glasscock E
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240170
[TBL] [Abstract][Full Text] [Related]
14. Musculoskeletal Features without Ataxia Associated with a Novel de novo Mutation in
Imbrici P; Accogli A; Blunck R; Altamura C; Iacomino M; D'adamo MC; Allegri A; Pedemonte M; Brolatti N; Vari S; Cataldi M; Capra V; Gustincich S; Zara F; Desaphy JF; Fiorillo C
Biomedicines; 2021 Jan; 9(1):. PubMed ID: 33466780
[TBL] [Abstract][Full Text] [Related]
15. kcna1a mutant zebrafish model episodic ataxia type 1 (EA1) with epilepsy and show response to first-line therapy carbamazepine.
Dogra D; Meza-Santoscoy PL; Gavrilovici C; Rehak R; de la Hoz CLR; Ibhazehiebo K; Rho JM; Kurrasch DM
Epilepsia; 2023 Aug; 64(8):2186-2199. PubMed ID: 37209379
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Functional Study of a De Novo Variant in the PVP Motif of Kv1.1 Channel Associated with Epilepsy, Developmental Delay and Ataxia.
Dinoi G; Morin M; Conte E; Mor Shaked H; Coppola MA; D'Adamo MC; Elpeleg O; Liantonio A; Hartmann I; De Luca A; Blunck R; Russo A; Imbrici P
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897654
[TBL] [Abstract][Full Text] [Related]
17. Clinical Spectrum of
Paulhus K; Ammerman L; Glasscock E
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316562
[TBL] [Abstract][Full Text] [Related]
18. Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability.
Eunson LH; Rea R; Zuberi SM; Youroukos S; Panayiotopoulos CP; Liguori R; Avoni P; McWilliam RC; Stephenson JB; Hanna MG; Kullmann DM; Spauschus A
Ann Neurol; 2000 Oct; 48(4):647-56. PubMed ID: 11026449
[TBL] [Abstract][Full Text] [Related]
19. New insights into the pathogenesis and therapeutics of episodic ataxia type 1.
D'Adamo MC; Hasan S; Guglielmi L; Servettini I; Cenciarini M; Catacuzzeno L; Franciolini F
Front Cell Neurosci; 2015; 9():317. PubMed ID: 26347608
[TBL] [Abstract][Full Text] [Related]
20. Dominant-negative mutation p.Arg324Thr in KCNA1 impairs Kv1.1 channel function in episodic ataxia.
Tristán-Clavijo E; Scholl FG; Macaya A; Iglesias G; Rojas AM; Lucas M; Castellano A; Martinez-Mir A
Mov Disord; 2016 Nov; 31(11):1743-1748. PubMed ID: 27477325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
